Table 2:
Enrollment characteristics of STOP Gout trial participants by serum urate (SU) outcome achieved during Phase 2 (n=764)
| Characteristic | SU Goal Achieved at 48 Weeks | SU Goal Not Achieved at 48 Weeks | P-value |
|---|---|---|---|
| N=618 | N=146 | ||
| DEMOGRAPHICS | |||
| Age, year, mean (SD) | 63.1 (12.1) | 58.5 (12.5) | <0.001 |
| Male, % | 97.9 | 100.0 | 0.14 |
| Race, % | <0.001 | ||
| Black/African American | 17.2 | 30.8 | |
| Other | 9.1 | 17.1 | |
| White/Caucasian | 73.8 | 52.1 | |
| Education, % | 0.17 | ||
| High School or less | 25.4 | 27.4 | |
| Some College or Associates Degree | 44.5 | 50.7 | |
| Bachelor’s Degree or higher | 28.2 | 19.2 | |
| Other/Not Stated | 1.9 | 2.7 | |
| CORMOBIDITY & HEALTH FACTORS | |||
| Chronic kidney disease – Stage III, % | 37.9 | 36.3 | 0.73 |
| Hypertension, % | 77.3 | 73.3 | 0.30 |
| Diabetes, % | 33.5 | 34.2 | 0.86 |
| Cardiovascular disease, % | 25.4 | 31.5 | 0.13 |
| Body mass index, kg/m2, % | 0.48 | ||
| < 25 (healthy) | 5.5 | 4.8 | |
| 25 ≤ BMI < 30 (overweight) | 28.5 | 23.3 | |
| 30 ≤ BMI < 35 (obese) | 30.1 | 30.1 | |
| ≥ 35 (morbidly obese) | 35.6 | 41.8 | |
| EQ-5D-3L index, mean (SD) | 0.7 (0.2) | 0.6 (0.2) | <0.001 |
| GOUT RELATED FACTORS | |||
| SU mg/dL, mean (SD) | 8.4 (1.3) | 9.1 (1.7) | <0.001 |
| Duration of gout, years, mean (SD) | 9.4 (10.7) | 11.3 (12.2) | 0.07 |
| Presence of tophi, % | 12.9 | 28.1 | <0.001 |
| Prior Allopurinol use, % | 37.2 | 39.0 | 0.68 |
| Diuretic use, % | 37.2 | 43.8 | 0.14 |
Abbreviations: SD, standard deviation; BMI, body mass index; EQ-5D-3L, EuroQol 5 Dimension-3 Level; SU, serum urate; SU goal < 6 mg/dl or < 5 mg/dl if tophi